For research use only. Not for therapeutic Use.
Mavorixafor Trihydrochloride（Cat No.:I020706）is a selective inhibitor of the CXCR4 chemokine receptor, developed for treating conditions associated with abnormal immune cell trafficking, such as WHIM syndrome (a rare immunodeficiency disorder) and certain cancers. By blocking the CXCR4 receptor, Mavorixafor prevents the retention of immune cells in the bone marrow, allowing their release into circulation to improve immune function. It is also being investigated for its potential to inhibit cancer metastasis and enhance the efficacy of immunotherapies. Its targeted mechanism offers promising therapeutic benefits in both genetic and oncological conditions.
| Catalog Number | I020706 |
| CAS Number | 2309699-17-8 |
| Molecular Formula | C₂₁H₃₀Cl₃N₅ |
| Purity | ≥95% |
| Target | CXCR; HIV |
| IUPAC Name | N'-(1H-benzimidazol-2-ylmethyl)-N'-[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]butane-1,4-diamine;trihydrochloride |
| InChI | InChI=1S/C21H27N5.3ClH/c22-12-3-4-14-26(15-20-24-17-9-1-2-10-18(17)25-20)19-11-5-7-16-8-6-13-23-21(16)19;;;/h1-2,6,8-10,13,19H,3-5,7,11-12,14-15,22H2,(H,24,25);3*1H/t19-;;;/m0.../s1 |
| InChIKey | FTHQTOSCZZCGHB-VLEZWVESSA-N |
| SMILES | C1C[C@@H](C2=C(C1)C=CC=N2)N(CCCCN)CC3=NC4=CC=CC=C4N3.Cl.Cl.Cl |
| Reference | [1]. Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88.<br>[2]. Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308. |
